FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897528174> ?p ?o ?g. }

• W2897528174 endingPage "e370" @default.
• W2897528174 startingPage "e369" @default.
• W2897528174 abstract "Chondrosarcomas (CHS) are considered as radio-resistant tumors requiring high-dose radiation therapy (RT). Skull base CHS are a validated indication for protontherapy. CHS from other anatomic sites are systematically contra-indicated for RT on an institution-dependent way, regardless of grade and quality of resection. The main objective of our study was to assess the impact of RT in extracranial CHS. Patients were extracted from the CONTICABASE, the database from the French Sarcoma Group (where all samples are reviewed for proper diagnosis), and additional data from the Rare Cancer Network were considered. All consecutive non metastatic extracranial CHS treated in a curative intent were included, regardless of RT. Between 2005 and 2014, 226 patients (125 men, 55%; median age 52 [range 11-90]), met inclusion criteria. Performance status was 0 in 50%, 1 in 46% and 2 in 4% of patients. ASA operability score was 0-1 in 65%, 2 in 20%, or >2. Primary site was a limb in 57%, thorax/spine in 24%, head and neck in 10% and abdomen/pelvis in 9%. It affected bone in 58% or soft-tissues in 42%. Grade was 1, 2, and 3 in 43%, 42%, and 15%; respectively. CHS was myxoïd, mesenchymal, dedifferentiated, periosteal in 28%, 10%, 5%, or 4%, respectively and NOS/other in most cases (53%). Surgery was performed in 89% with en bloc resection, and 76% of patients were considered as R0. RT was performed in 85 (37,6%) patients combined to surgery or as exclusive local treatment. Among irradiated patients 46 (54%), 18 (21%), 15 (18%) and 6 (7%) were grade 2, 1, 3 and unclassified respectively. Mean dose was 54Gy (range 26-70Gy). Three-dimensional RT, Intensity-modulated RT and protontherapy were used in 71%, 24% and 5% respectively. Thirty-nine (17%) patients had adjuvant chemotherapy. With a median follow-up period of 54,5 months (range 1-532), there were 84 (37,1%) relapses including 49 local relapses within median 48 months, 13 regional within 71 months, and 65 metastatic ones within 42 months. At last follow-up, 56% of the patients were alive without disease; and 11% and 29% of the patients were alive or dead with disease, respectively. Of the 62 locoregional relapsing patients, there were 15 (24%) in the irradiated vs 47 (76%) in the non-irradiated patients. Late grade 3 or more toxicity was noted in 3 patients. Extracranial chondrosarcoma is a rare entity but this large database study seems to show that these patients have a better outcome when RT (postoperative or exclusive) is administered." @default.
• W2897528174 created "2018-10-26" @default.
• W2897528174 creator A5004321308 @default.
• W2897528174 creator A5008540435 @default.
• W2897528174 creator A5012250582 @default.
• W2897528174 creator A5019263878 @default.
• W2897528174 creator A5023740879 @default.
• W2897528174 creator A5026826746 @default.
• W2897528174 creator A5032986745 @default.
• W2897528174 creator A5034083299 @default.
• W2897528174 creator A5037589425 @default.
• W2897528174 creator A5044730023 @default.
• W2897528174 creator A5045147733 @default.
• W2897528174 creator A5045172802 @default.
• W2897528174 creator A5047514488 @default.
• W2897528174 creator A5066266071 @default.
• W2897528174 creator A5071020688 @default.
• W2897528174 creator A5090466794 @default.
• W2897528174 creator A5090712768 @default.
• W2897528174 date "2018-11-01" @default.
• W2897528174 modified "2023-10-18" @default.
• W2897528174 title "Radiation Therapy in Extracranial Chondrosarcomas: A Multicenter French Sarcoma Group and Rare Cancer Network Study" @default.
• W2897528174 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1105" @default.
• W2897528174 hasPublicationYear "2018" @default.
• W2897528174 type Work @default.
• W2897528174 sameAs 2897528174 @default.
• W2897528174 citedByCount "0" @default.
• W2897528174 crossrefType "journal-article" @default.
• W2897528174 hasAuthorship W2897528174A5004321308 @default.
• W2897528174 hasAuthorship W2897528174A5008540435 @default.
• W2897528174 hasAuthorship W2897528174A5012250582 @default.
• W2897528174 hasAuthorship W2897528174A5019263878 @default.
• W2897528174 hasAuthorship W2897528174A5023740879 @default.
• W2897528174 hasAuthorship W2897528174A5026826746 @default.
• W2897528174 hasAuthorship W2897528174A5032986745 @default.
• W2897528174 hasAuthorship W2897528174A5034083299 @default.
• W2897528174 hasAuthorship W2897528174A5037589425 @default.
• W2897528174 hasAuthorship W2897528174A5044730023 @default.
• W2897528174 hasAuthorship W2897528174A5045147733 @default.
• W2897528174 hasAuthorship W2897528174A5045172802 @default.
• W2897528174 hasAuthorship W2897528174A5047514488 @default.
• W2897528174 hasAuthorship W2897528174A5066266071 @default.
• W2897528174 hasAuthorship W2897528174A5071020688 @default.
• W2897528174 hasAuthorship W2897528174A5090466794 @default.
• W2897528174 hasAuthorship W2897528174A5090712768 @default.
• W2897528174 hasConcept C105702510 @default.
• W2897528174 hasConcept C126838900 @default.
• W2897528174 hasConcept C136948725 @default.
• W2897528174 hasConcept C141071460 @default.
• W2897528174 hasConcept C142724271 @default.
• W2897528174 hasConcept C2776302905 @default.
• W2897528174 hasConcept C2778256501 @default.
• W2897528174 hasConcept C2778357063 @default.
• W2897528174 hasConcept C2779300802 @default.
• W2897528174 hasConcept C2779983558 @default.
• W2897528174 hasConcept C509974204 @default.
• W2897528174 hasConcept C71924100 @default.
• W2897528174 hasConcept C97834683 @default.
• W2897528174 hasConceptScore W2897528174C105702510 @default.
• W2897528174 hasConceptScore W2897528174C126838900 @default.
• W2897528174 hasConceptScore W2897528174C136948725 @default.
• W2897528174 hasConceptScore W2897528174C141071460 @default.
• W2897528174 hasConceptScore W2897528174C142724271 @default.
• W2897528174 hasConceptScore W2897528174C2776302905 @default.
• W2897528174 hasConceptScore W2897528174C2778256501 @default.
• W2897528174 hasConceptScore W2897528174C2778357063 @default.
• W2897528174 hasConceptScore W2897528174C2779300802 @default.
• W2897528174 hasConceptScore W2897528174C2779983558 @default.
• W2897528174 hasConceptScore W2897528174C509974204 @default.
• W2897528174 hasConceptScore W2897528174C71924100 @default.
• W2897528174 hasConceptScore W2897528174C97834683 @default.
• W2897528174 hasIssue "3" @default.
• W2897528174 hasLocation W28975281741 @default.
• W2897528174 hasOpenAccess W2897528174 @default.
• W2897528174 hasPrimaryLocation W28975281741 @default.
• W2897528174 hasRelatedWork W2062678678 @default.
• W2897528174 hasRelatedWork W2063449699 @default.
• W2897528174 hasRelatedWork W2139075368 @default.
• W2897528174 hasRelatedWork W2152936647 @default.
• W2897528174 hasRelatedWork W2515161019 @default.
• W2897528174 hasRelatedWork W2963164130 @default.
• W2897528174 hasRelatedWork W2986846180 @default.
• W2897528174 hasRelatedWork W3013035464 @default.
• W2897528174 hasRelatedWork W3104523372 @default.
• W2897528174 hasRelatedWork W3161389246 @default.
• W2897528174 hasVolume "102" @default.
• W2897528174 isParatext "false" @default.
• W2897528174 isRetracted "false" @default.
• W2897528174 magId "2897528174" @default.
• W2897528174 workType "article" @default.